HealthEquity Confirms Non-Emerging Growth Status in 8-K Filing
Ticker: HQY · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1428336
| Field | Detail |
|---|---|
| Company | Healthequity, INC. (HQY) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, 8-K, corporate-governance
TL;DR
**HealthEquity is NOT an emerging growth company, meaning full SEC reporting applies.**
AI Summary
HealthEquity, Inc. filed an 8-K on January 8, 2024, primarily to disclose that it is not an emerging growth company. This filing, under Regulation FD Disclosure, confirms its status as a well-established public company. For investors, this means HealthEquity is subject to the full range of SEC reporting requirements, which generally implies greater transparency and regulatory oversight compared to emerging growth companies, potentially offering more robust information for investment decisions.
Why It Matters
This filing clarifies HealthEquity's regulatory status, confirming it is subject to full public company reporting requirements, which can impact investor perception of transparency and maturity.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not indicate any operational or financial risks for the company.
Analyst Insight
A smart investor would note this administrative filing confirms HealthEquity's mature regulatory status, implying standard transparency and reporting, and would continue to focus on operational and financial performance rather than regulatory status changes.
Key Players & Entities
- HEALTHEQUITY, INC. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported and filing date
- Delaware (company) — state of incorporation for HealthEquity, Inc.
- 001-36568 (dollar_amount) — Commission File Number for HealthEquity, Inc.
- HQY (company) — trading symbol for HealthEquity, Inc. common stock
- The NASDAQ Global Select Market (company) — exchange where HealthEquity, Inc. common stock is registered
FAQ
What was the primary purpose of HealthEquity, Inc.'s 8-K filing on January 8, 2024?
The primary purpose was to disclose information under Regulation FD Disclosure and to confirm that HealthEquity, Inc. is not an 'emerging growth company' as defined by SEC rules.
What is HealthEquity, Inc.'s trading symbol and on which exchange is its common stock registered?
HealthEquity, Inc.'s trading symbol is HQY, and its common stock is registered on The NASDAQ Global Select Market.
What does it mean for HealthEquity, Inc. to not be an 'emerging growth company'?
It means HealthEquity, Inc. does not qualify for certain scaled disclosure requirements and exemptions available to emerging growth companies under the Securities Act of 1933 and the Securities Exchange Act of 1934, and is subject to full public company reporting obligations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is the state of incorporation for HealthEquity, Inc.?
HealthEquity, Inc. is incorporated in Delaware.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-08 09:01:46
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share HQY The NASDAQ Global Select
Filing Documents
- hqy-20240108.htm (8-K) — 25KB
- jpmhccconf2024vf.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 10KB
- 0001428336-24-000002.txt ( ) — 188KB
- hqy-20240108.xsd (EX-101.SCH) — 2KB
- hqy-20240108_lab.xml (EX-101.LAB) — 25KB
- hqy-20240108_pre.xml (EX-101.PRE) — 13KB
- hqy-20240108_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On January 8, 2024, HealthEquity, Inc. (the "Company") issued a press release, attached as Exhibit 99.1 to this current report on Form 8-K, announcing its estimated year-end sales results for its fiscal year ending January 31, 2024 and that it will discuss these results and estimates, along with additional information regarding HSA cash maturities and capital allocation considerations, during its virtual presentation at the 42 nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 4:30 PM Pacific Time. An audio webcast of the presentation along with a copy of the Company's presentation material from the conference will be available through the investor page at the Company website: ir.healthequity.com. The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by HealthEquity, Inc. dated January 8, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEALTHEQUITY, INC. Date: January 8, 2024 By: /s/ James Lucania Name: James Lucania Title: Executive Vice President and Chief Financial Officer